A newly published real-world data (RWD) study in Breast Cancer: Targets and Therapy takes a look at the clinical factors and sociodemographics of patients with HER2-low and HER2-zero triple-negative breast cancer at the Brazilian National Cancer Institute. Analysis shows that that there were no significant differences between the two groups in terms of sociodemographic traits, survival outcomes, and clinical behavior.
According to the authors, “The categorization of the HER2 biomarker into a binary status has been subject to significant scrutiny in light of recent clinical trials, which have demonstrated promising response rates and improved survival outcomes in patients with HER2-low tumors treated with anti-HER2 ADCs. This emerging evidence has led proponents to advocate for a more nuanced understanding of HER2 expression as a continuous spectrum biomarker. However, there remains an unmet need to comprehensively characterize the extensive tumor heterogeneity observed in the context of TNBC. The primary findings of the current study indicate that sociodemographic and clinicopathological factors, response rates to neoadjuvant chemotherapy and survival outcomes do not differ significantly across TNBC subgroups stratified by varying levels of HER2 expression.”
To read more, click here.
(Source: Breast Cancer: Targets and Therapy, May 8th, 2023)